Coming Soon: "Shine the LIght on Sickle Cell" in celebration of World Sickle Cell Day - June 19

What types of clinical studies are being conducted?

Clinical studies in Maryland, Delaware, and Washington, DC, are looking for more participants. Answer the questions below to find one that fits your situation.

Open to sickle cell patients ages 12-65, this trial is studying the effectiveness of a new medication that may help blood cells hold onto more oxygen.

Ask your doctor about study NCT03036813

CONTACT: Global Blood Therapeutics / Center for Blood and Cancer Disorders Natalie Bongiorno, RN, 301-571-2016, nbongiorno@ccbdmd.com

Studying the Safety and Effectiveness of the Drug Rivipansel in the Treatment of Sickle Cell Crisis

Participants must be at least six years old.

Participating medical facilities in the mid-Atlantic region include: Medstar Health Research Institute (DC), Howard University Hospital (DC), University of Maryland Medical System Investigational Pharmacy (MD), University of Maryland Medical System (MD), Johns Hopkins Medicine (MD), The Johns Hopkins University School of Medicine (MD), and The Johns Hopkins Hospital (MD)

Ask your doctor about study # NCT02187003

Contact information is located on the Pfizer website.

 

Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients with Crisis

Researchers are studying a new drug that may decrease the time a patient is in crisis and help them go home from the hospital more quickly. Participants must be more than 18 years old.

Ask your doctor about study # NCT02411708

CONTACT:

University of Maryland School of Medicine

Baltimore, Maryland, United States, 21201-1559

Dana Beach, RN, 410-328-7635, dbeach@em.umaryland.edu

Gentry R. Wilkerson, MD, 410-328-8025, gwilkerson@em.umaryland.edu

Johns Hopkins University School of Medicine

Baltimore, Maryland, United States, 21205

Sophie Lanzkron, MD, 410-502-8642, slanzkr@jhmi.edu

Studying a New Transplant Treatment for People with Sickle Cell Disease

Researchers want to improve the success and reduce the complications for blood stem cell transplants. This might allow more people to have a transplant. The study includes both the sickle cell patient and a close relative who is at least half a tissue match.

Ask your doctor about study # NCT03077542

CONTACT:

National Institutes of Health Clinical Center

Bethesda, Maryland, United States, 20892

Patient Recruitment and Public Liaison Office 800-411-1222

prpl@mail.cc.nih.gov

 

Studying the Safety and Effectiveness of the Drug LentiGlobin to Treat Severe Sickle Cell Disease

For adults who experience crisis twice a year on average, this study is looking at how well the drug LentiGlobin works to stop cell sickling after a stem-cell transplant.

Ask your doctor about study # NCT02140554

CONTACT: clinicaltrials@bluebirdbio.com

 

Improving the Results of Bone Marrow Transplantation for Sickle Cell Patients

The purpose of this study is to explore the use of a bone marrow transplant treatment that, uses a low dose of radiation instead of chemotherapy. This type procedure does not destroy the patient’s bone marrow. The trial is open to patients who meet the criteria and are between 2 and 80 years old.

Ask your doctor about study # NCT00061568

CONTACT:

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, United States, 20892

Patient Recruitment and Public Liaison Office 800-411-1222, prpl@mail.cc.nih.gov

Mary E. Link, R.N., (301) 402-3087, linkme@nhlbi.nih.gov

John F Tisdale, M.D., (301) 402-6497, johntis@mail.nih.gov

Stem Cell Transplantation for Children With Sickle Cell Disease

The purpose of this study is to assess the safety and stem cell transplantation. The trial is open to patients up to 22 years old, who have a related donor.

Ask your doctor about study # NCT02165007

CONTACT:

Childrens National Medical Center

Washington, District of Columbia, United States, 20010

Allistair Abraham, MD,   202-476-5772, AAbraham@childrensnational.org

Fahmida Hoq, MBBS, MS, 202-476-3634, fhoq@cnmc.org

 

Treatment to Prevent Brain Injury in Patients with Sickle Cell Disease

For children between 1 and 4 years old, this trial is studying the effectiveness of hydroxyurea versus placebo to reduce central nervous system complications. Half of the participants will receive a placebo and neither the study doctors nor the participants will know which treatment they are receiving.

Ask your doctor about study # NCT01389024

CONTACT:

Sinai Hospital

Baltimore, Maryland, United States, 21215

Jason Fixler, MD, 410-601-6175, Jfixler@lifebridgehealth.org

Johns Hopkins Hospital

Baltimore, Maryland, United States, 21287

Diane Weiss, BA, 410-955-6132, dweiss14@jhmi.edu

Lydia Pecker, MD, 410-955-6732, lpecker1@jhmi.edu

Ask your doctor about study # NCT02239016

CONTACT:

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, United States, 20892

Patient Recruitment and Public Liaison Office 800-411-1222, prpl@mail.cc.nih.gov

This study will determine the best ways to collect, process and store umbilical cord blood from babies with sickle cell disease, sickle cell trait, and unaffected babies. Pregnant women between 18 and 45 years of age who are at risk of having an infant with sickle cell disease may be eligible to participate.

Ask your doctor about study # NCT00012545

CONTACT:

National Institutes of Health Clinical Center, 9000 Rockville Pike   Recruiting

Bethesda, Maryland, United States, 20892

Wynona Coles, (301) 402-2104, wcoles@nhlbi.nih.gov

John F Tisdale, M.D., (301) 402-6497, johntis@mail.nih.gov

Tracking the Natural History of Sickle Cell Disease

For patients two years old or older, the goal of this study is to collect blood and tissue samples from sickle cell patients to help researchers track the progression of the disease. No experimental treatments are involved.

Ask your doctor about study # NCT00081523

CONTACT:

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, United States, 20892

Patient Recruitment and Public Liaison Office 800-411-1222, prpl@mail.cc.nih.gov

Darlene Allen, (301) 435-1495, darlenea@nhlbi.nih.gov

 

A Software Platform to Help Patients Manage Pain

Open to patients between 8 and 21 years old, this trial wants to see if a mobile phone application can help decrease the need for repeat admission to the hospital because of sickle cell pain.

Ask your doctor about study # NCT03006718

CONTACT: Children’s National Medical Center

Washington, District of Columbia, United States, 20010

Zenaide Quezado, MD, 202-476-2025, zquezado@childrensnational.org

Want to see a full list of studies around the country?

Talk to your doctor.
It's easy!

Take our “Ask Your Doctor” sheet to your physician to start a conversation about clinical studies. There are 5 questions that will help you learn more about studies in your area.

Want more information about clinical studies?

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. Explore 259,383 research studies in all 50 states and in 201 countries.

ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine.

The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.

FDA is an agency within the Department of Health and Human Services.

The FDA's organization consists of the Office of the Commissioner and four directorates overseeing the core functions of the agency: Medical Products and Tobacco, Foods, Global Regulatory Operations and Policy, and Operations.

CDC laboratories routinely work with some of the most deadly germs in the world – identifying health threats and conducting vital public health research. CDC constantly develops and reviews extensive laboratory guidelines and procedures to protect both the public and laboratory workers.